Teva Pharmaceuticals Files 8-K on Security Holder Vote
Ticker: TEVJF · Form: 8-K · Filed: Jun 6, 2024 · CIK: 818686
| Field | Detail |
|---|---|
| Company | Teva Pharmaceutical Industries Ltd (TEVJF) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: TEVA
TL;DR
Teva's voting on something important with shareholders.
AI Summary
On June 6, 2024, TEVA PHARMACEUTICAL INDUSTRIES LTD filed an 8-K report indicating a submission of matters to a vote of security holders. The filing does not contain specific details about the nature of the vote or any associated financial figures.
Why It Matters
This filing signals that Teva Pharmaceuticals is engaging its shareholders on a specific matter requiring their approval, which could impact corporate governance or strategic decisions.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any immediate financial risks or significant operational changes.
Key Players & Entities
- TEVA PHARMACEUTICAL INDUSTRIES LTD (company) — Registrant
- June 6, 2024 (date) — Date of Report
FAQ
What specific matter is being submitted for a vote of security holders?
The filing does not specify the exact matter being submitted for a vote.
When was the earliest event reported in this filing?
The earliest event reported was on June 6, 2024.
What is Teva Pharmaceutical Industries Ltd's principal executive office address?
The principal executive office is located at 124 Dvora Hanevi’a Street, Tel Aviv 6944020, Israel.
What is Teva's Commission File Number?
Teva's Commission File Number is 001-16174.
What is the Standard Industrial Classification code for Teva Pharmaceutical Industries Ltd?
The Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.
Filing Stats: 654 words · 3 min read · ~2 pages · Grade level 15.9 · Accepted 2024-06-06 16:05:54
Filing Documents
- d841419d8k.htm (8-K) — 37KB
- 0001193125-24-156043.txt ( ) — 153KB
- teva-20240606.xsd (EX-101.SCH) — 3KB
- teva-20240606_lab.xml (EX-101.LAB) — 17KB
- teva-20240606_pre.xml (EX-101.PRE) — 11KB
- d841419d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TEVA PHARMACEUTICAL INDUSTRIES LIMITED Date: June 6, 2024 By: /s/ Eli Kalif Name: Eli Kalif Title: Executive Vice President, Chief Financial Officer